{
    "nct_id": "NCT04384146",
    "official_title": "PROMISE 006: A Phase I Study of up to 3 Cycles of Cyclical Hypofractionated Palliative Radiation (Quad Shot) for Lung Tumors in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)",
    "inclusion_criteria": "* Histologically confirmed non-small cell lung cancer with metastatic disease detected on cross-sectional imaging with a plan for one of the following systemic therapies:\n\n  * Carboplatin/paclitaxel\n  * Carboplatin/paclitaxel/pembrolizumab\n  * Carboplatin/pemetrexed\n  * Carboplatin/pemetrexed/pembrolizumab\n  * Pembrolizumab (single agent or in combination with other regimens in this list)\n  * Cisplatin/pemetrexed\n  * Cisplatin/pemetrexed/pembrolizumab\n  * Pemetrexed/pembrolizumab\n  * Pemetrexed\n  * Nivolumab (single agent or in combination with other regimens in this list)\n  * Ipilimumab/nivolumab\n  * Carboplatin/etoposide\n  * Carboplatin/etoposide/atezolizumab\n  * Cisplatin/etoposide\n  * Cisplatin/etoposide/atezolizumab\n  * Durvalumab (single agent or in combination with other regimens in this list)\n  * Atezolizumab (single agent or in combination with other regimens in this list)\n* Patients eligible for the systemic therapy regimens notes\n* Patients with Stage IV NSCLC who have symptomatic (defined by patient-reported cough, dyspnea, or hemoptysis) or near-symptomatic (determined radiographically to be threatening the airway, esophagus or vasculature) centrally located.\n* KPS ≥ 60\n* Age ≥ 18 years.\n* Able to provide informed consent.\n* Patients at reproductive potential must agree to practice an effective contraceptive method.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances.\n* Serious medical co-morbidities precluding radiotherapy.\n* Pregnant or breast-feeding women.",
    "miscellaneous_criteria": ""
}